Experts Mixed on MFN Drug Pricing Impact

In a new survey of health policy experts conducted by the Cornell Health Policy Center, respondents expressed uncertainty about the effects of a most favored nation (MFN) prescription drug pricing policy whereby the US would tie drug prices to those paid in peer nations. Half of the experts, members of the Cornell Health Policy Insight Panel, indicated MFN pricing would substantially reduce net US drug prices, while half disagreed or were uncertain about the effects.